Upside case
Bull case
$321+112.5%
PODD would need investors to value it at roughly 51x earnings — about 27x more generous than today's 24x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated May 1, 2026
Insulet Corporation (PODD) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
50
analysts
35 bullish · 3 bearish · 50 covering PODD
Strong Buy
0
Buy
35
Hold
12
Sell
3
Strong Sell
0
Consensus Target
$339
+124.3% vs today
Scenario Range
— – $321
Model bear to bull value window
Coverage
50
Published analyst ratings
Valuation Context
23.8x
Forward P/E · Market cap $10.6B
PODD price targets
Three scenarios for where PODD stock could go
Current
~$151
Confidence
81 / 100
Updated
May 1, 2026
Where we are now
Current · $151
Base
$329
Bull
$321
Market caseClosest to today
Base case
$329+117.8%
At 52x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
—
The bear case reflects a scenario where earnings shortfalls or multiple compression combine to materially reduce the stock from its current level.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Insulet Corporation
PODD · NASDAQHealthcareMedical - DevicesDecember year-end
Insulet Corporation is a medical device company that makes tubeless insulin pumps for people with diabetes. It generates revenue primarily from sales of its disposable Omnipod pods — which account for the vast majority of its income — along with sales of its handheld controllers and related supplies. Its key competitive advantage is its unique tubeless, waterproof design that offers greater freedom and convenience compared to traditional tube-based insulin pumps.
Market Cap
$10.6B
Revenue TTM
$2.9B
Net Income TTM
$303M
Net Margin
10.4%
PODD Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
92%Exceptional
12 quarters tracked
Revenue Beat Rate
92%Exceptional
vs consensus estimates
Avg EPS Surprise
+37.0%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 4 of 4Q3 2025
EPS
$1.17/$0.92
Revenue
$649M/$614M
Q4 2025
EPS
$1.24/$1.14
Revenue
$706M/$678M
Q1 2026
EPS
$1.55/$1.47
Revenue
$784M/$769M
Q2 2026
EPS
$1.42/$1.19
Revenue
$762M/$730M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $1.17/$0.92 | +27.2% | $649M/$614M | +5.7% |
| Q4 2025 | $1.24/$1.14 | +8.8% | $706M/$678M | +4.1% |
| Q1 2026 | $1.55/$1.47 | +5.4% | $784M/$769M | +1.9% |
| Q2 2026 | $1.42/$1.19 | +19.3% | $762M/$730M | +4.4% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$3.3B
+29.8% YoY
FY2
$4.1B
+24.8% YoY
EPS Outlook
FY1
$5.65
+62.2% YoY
FY2
$7.58
+34.1% YoY
Trailing FCF (TTM)$416M
FCF Margin: 14.3%
Next Earnings
May 6, 2026
Expected EPS
$1.19
Expected Revenue
$730M
PODD beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
PODD Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $2.7B
Product Mix
Latest annual revenue by segment or product family
International Omnipod
98.7%
+31.6% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
UNITED STATES
72.1%
+26.2% YoY
Tap, hover, or focus a slice to inspect segment detail.
International Omnipod is the largest disclosed segment at 98.7% of FY 2025 revenue, up 31.6% YoY.
UNITED STATES is the largest reported region at 72.1%, up 26.2% YoY.
PODD Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Significantly Undervalued
Fair value est. $578 — implies +230.4% from today's price.
Upside to Fair Value
230.4%
potential upside
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
PODD
43.4x
vs
S&P 500
25.2x
+72% premium
vs Healthcare Trailing P/E
PODD
43.4x
vs
Healthcare
22.1x
+96% premium
vs PODD 5Y Avg P/E
Today
43.4x
vs
5Y Average
66.9x
35% discount
Forward PE
23.8x
S&P 500
19.1x
+25%
Healthcare
19.0x
+25%
5Y Avg
—
—
Trailing PE
43.4x
S&P 500
25.2x
+72%
Healthcare
22.1x
+96%
5Y Avg
66.9x
-35%
PEG Ratio
0.42x
S&P 500
1.75x
-76%
Healthcare
1.52x
-72%
5Y Avg
—
—
EV/EBITDA
18.7x
S&P 500
15.3x
+22%
Healthcare
14.1x
+32%
5Y Avg
47.8x
-61%
Price/FCF
28.1x
S&P 500
21.3x
+32%
Healthcare
18.7x
+51%
5Y Avg
58.6x
-52%
Price/Sales
3.9x
S&P 500
3.1x
+25%
Healthcare
2.8x
+38%
5Y Avg
11.7x
-67%
Dividend Yield
—
S&P 500
1.88%
—
Healthcare
1.40%
—
5Y Avg
—
—
| Metric | PODD | S&P 500 | Healthcare | 5Y Avg PODD |
|---|---|---|---|---|
| Forward PE | 23.8x | 19.1x+25% | 19.0x+25% | — |
| Trailing PE | 43.4x | 25.2x+72% | 22.1x+96% | 66.9x-35% |
| PEG Ratio | 0.42x | 1.75x-76% | 1.52x-72% | — |
| EV/EBITDA | 18.7x | 15.3x+22% | 14.1x+32% | 47.8x-61% |
| Price/FCF | 28.1x | 21.3x+32% | 18.7x+51% | 58.6x-52% |
| Price/Sales | 3.9x | 3.1x+25% | 2.8x+38% | 11.7x-67% |
| Dividend Yield | — | 1.88% | 1.40% | — |
PODD trades above S&P 500 benchmarks on 5 of 6 measured multiples — commands a broad premium across most valuation dimensions.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolPODD Financial Health
Verdict
Strong
PODD generates $416M in free cash flow at a 14.3% margin — 20.1% ROIC signals a durable competitive advantage.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$2.9B
Revenue Growth
TTM vs prior year
+31.9%
Gross Margin
Gross profit as a share of revenue
71.0%
Operating Margin
Operating income divided by revenue
17.5%
Net Margin
Net income divided by revenue
10.4%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$4.31
Free Cash Flow (TTM)
Cash generation after capex
$416M
FCF Margin
FCF as share of revenue — the primary cash quality signal
14.3%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
20.1%
ROA
Return on assets, trailing twelve months
9.6%
Cash & Equivalents
Liquid assets on the balance sheet
$716M
Net Debt
Total debt minus cash
$335M
Debt Serviceability
Net debt as a multiple of annual free cash flow
0.8× FCF
~0.8 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
21.4%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
0.6%
Dividend
—
Buyback
0.6%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$60M
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Declining as buybacks retire shares
70M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pagePODD Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 29, 2026
High Risk
Competition
The insulin pump market is increasingly competitive, with established players like Tandem Diabetes Care and Medtronic advancing their product pipelines. This competition raises concerns about pricing pressure and the potential impact on Insulet's market share.
High Risk
Product Development and Innovation
Insulet's success is heavily reliant on its innovation pipeline, including the anticipated launches of Omnipod 6 in FY27 and a closed-loop system for Type 2 diabetes in FY28. Rapid competitive innovation poses a significant risk to the company's market position.
High Risk
Device Correction and Safety Concerns
Insulet issued a voluntary medical device correction for certain Omnipod 5 pod lots due to a design defect causing insulin leakage, which has been linked to serious adverse events. This issue has led to a drop in share price and investigations into potential concealment of the defect.
Medium
Regulatory and Reimbursement Risks
Government healthcare spending directly impacts reimbursement rates, and political shifts in coverage mandates can alter the total addressable market for Insulet. Additionally, evolving U.S. tariff policies create supply chain and cost uncertainty.
Medium
Valuation and Market Perception
Insulet's stock has traded at high multiples, raising concerns about potential multiple compression. While some analysts view it as undervalued based on future cash flows, the current market valuation suggests investors are paying a premium for expected strong execution.
Medium
Dependence on Key Products
Insulet has a heavy reliance on its Omnipod products, which could pose risks if market dynamics shift or if competitive products gain traction.
Lower
Supply Chain Dependencies
Supply chain issues and geopolitical instability pose risks to Insulet's global operations, potentially affecting production and distribution.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why PODD Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 29, 2026
Market Leadership and Growth Potential
Insulet is a leader in innovative insulin delivery systems and is well-positioned for sustained growth. The company's Omnipod platform, including the Omnipod 5 automated insulin delivery system, is a key driver of this potential.
Strong Financial Performance and Future Outlook
Insulet is described as a profitable, hyper-growth company with strong financial performance. Analysts project significant earnings per share (EPS) growth in the coming years, with revenue expected to expand by over 20% annually.
Analyst Confidence
A high percentage of analysts recommend buying the stock, with many issuing 'Strong Buy' ratings. The average analyst price target indicates a substantial potential increase in the stock price.
Product Innovation and Expansion
Insulet is expanding into new markets, including primary care and the closed-loop system market for Type 2 diabetes. The company's ongoing efforts in research and development for its Omnipod 6 and closed-loop systems are seen as crucial for long-term success.
Undervalued Stock Potential
Some analyses suggest the stock is undervalued, with a fair value estimate significantly higher than its current trading price.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
PODD Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$151.17
52W Range Position
1%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$148.31
+1.9% from the low
52-Week High
$354.88
-57.4% from the high
1 Month
-25.71%
3 Month
-37.52%
YTD
-46.6%
1 Year
-41.6%
3Y CAGR
-22.0%
5Y CAGR
-9.8%
10Y CAGR
+17.6%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
PODD vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
23.8x
vs 15.7x median
+51% above peer median
Revenue Growth
+29.8%
vs +7.9% median
+277% above peer median
Net Margin
10.4%
vs 7.7% median
+36% above peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
POD PODD Insulet Corporation | $10.6B | 23.8x | +29.8% | 10.4% | Buy | +124.3% |
DXC DXCM DexCom, Inc. | $23.3B | 24.2x | +12.9% | 19.3% | Buy | +34.0% |
TND TNDM Tandem Diabetes Care, Inc. | $1.2B | — | +7.9% | -20.2% | Buy | +75.4% |
NVC NVCR NovoCure Limited | $1.9B | — | +6.5% | -25.7% | Buy | +103.1% |
ITG ITGR Integer Holdings Corporation | $3.0B | 13.3x | +7.6% | 7.7% | Buy | +13.6% |
ABT ABT Abbott Laboratories | $150.0B | 15.7x | +9.3% | 31.9% | Buy | +49.2% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
PODD Dividend and Capital Return
PODD returns 0.6% annually — null% through dividends and 0.6% through buybacks.
Dividend UnknownFCF Unknown
Total Shareholder Yield
0.6%
Dividend + buyback return per year
Buyback Yield
0.6%
Dividend Yield
—
Payout Ratio
—
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.00
Growth Streak
Consecutive years of dividend increases
0Y
3Y Div CAGR
—
5Y Div CAGR
—
Ex-Dividend Date
—
Payment Cadence
—
0 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$60M
Estimated Shares Retired
394.3K
Approx. Share Reduction
0.6%
Shares Outstanding
Current diluted share count from the screening snapshot
70M
At 0.6%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
FAQ
7 questionsPODD Investor Questions
Common questions answered from live analyst data and company financials.
01Is Insulet Corporation (PODD) stock a buy or sell in 2026?
Insulet Corporation (PODD) is rated Buy by Wall Street analysts as of 2026. Of 50 analysts covering the stock, 35 rate it Buy or Strong Buy, 12 rate it Hold, and 3 rate it Sell or Strong Sell. The consensus 12-month price target is $339, implying +124.3% from the current price of $151.
02What is the PODD stock price target for 2026?
The Wall Street consensus price target for PODD is $339 based on 50 analyst estimates. The high-end target is $435 (+187.8% from today), and the low-end target is $220 (+45.5%). The base case model target is $329.
03Is Insulet Corporation (PODD) stock overvalued in 2026?
PODD trades at 23.8x times forward earnings. The stock trades at a notable premium to the broad market, which is typical for businesses with strong free cash flow and above-average growth expectations. Based on current multiples versus the peer group, the relative model signals significantly undervalued. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Insulet Corporation (PODD) stock in 2026?
The primary risks for PODD in 2026 are: (1) Competition — The insulin pump market is increasingly competitive, with established players like Tandem Diabetes Care and Medtronic advancing their product pipelines. (2) Product Development and Innovation — Insulet's success is heavily reliant on its innovation pipeline, including the anticipated launches of Omnipod 6 in FY27 and a closed-loop system for Type 2 diabetes in FY28. (3) Device Correction and Safety Concerns — Insulet issued a voluntary medical device correction for certain Omnipod 5 pod lots due to a design defect causing insulin leakage, which has been linked to serious adverse events. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Insulet Corporation's revenue and earnings forecast?
Analyst consensus estimates PODD will report consensus revenue of $3.3B (+29.8% year-over-year) and EPS of $5.65 (+62.2% year-over-year) for the upcoming fiscal year. The following year, analysts project $4.1B in revenue.
06When does Insulet Corporation (PODD) report its next earnings?
Insulet Corporation is expected to report its next earnings on approximately 2026-05-06. Consensus expects EPS of $1.19 and revenue of $730M. Over recent quarters, PODD has beaten EPS estimates 92% of the time.
07How much free cash flow does Insulet Corporation generate?
Insulet Corporation (PODD) generated $416M in free cash flow over the trailing twelve months — a free cash flow margin of 14.3%. PODD returns capital to shareholders through and share repurchases ($60M TTM).